A syndrome of high [Pi] in serum, hyperphosphatemia, is a risk factor in chronic kidney disease, afflicting over six hundred million people globally (70), and Xpr1 could be a possible therapeutic target for hyperphosphatemia (52). This evidence concerns the gene XPR1 and hyperphosphatemia.